Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 7,500 shares at $2.96 ($22K) on 2023-04-27, disclosed to the SEC on 2023-04-27.
Open-market purchase of $22k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.00 | 5,571 | $17K | 74.5% |
| 2 | $2.97 | 425 | $1K | 5.6% |
| 3 | $2.96 | 1,504 | $4K | 19.9% |
| Total | $2.99 avg | 7,500 | $22K | 100% |
| Filing → |
| AVTX | BUY | 2023-06-14 | $64K | — | Filing → |
| AVTX | BUY | 2023-06-09 | $56K | — | Filing → |
| AVTX | BUY | 2023-06-02 | $2K | — | Filing → |